Symptom rating scales and outcome in schizophrenia

British Journal of Psychiatry

Volumn 191, Issue SUPPL. 50, 2007, Pages

  Mortimer, Ann M ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE;

BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LONG TERM CARE; NURSING CARE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; REMISSION; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL STATUS; TREATMENT DURATION;

EID: 84858108170     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.191.50.s7     Document Type: Review

References (82)

1. Addington, D., Addington, J., Maticka-Tyndale, E., et al (1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6, 201-208.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorder (4th edn). APA.
3. Andreasen, N. (1902) Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry, 39, 784-788.
4. Andreasen, N. (1984a) Scale for the Assessment of Negative Symptoms (SANS). Univeristy of Iowa.
5. Andreasen, N. (1984b) Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa.
6. Andreasen, N. & Olsen, S. (1982) Negative v positive schizophrenia: definition and validation. Archives of General Psychiatry, 39, 789-794.
7. Andreasen, N., Carpenter, W., Kane, J., et al (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry, 162, 441-449.
8. Andrews, G., Peters, L., & Teeson, M. (1994) The Measurement of Consumer Outcome in Mental Health. Australian Health Outcomes Collaboration.
9. Bell, M., Milstein, R., Beam-Goulet, J., et al (1992) The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability and predictive validity. Journal of Nervous and Mental Disorders, 180, 723-728.
10. Bell, M., Lysaker, P., Milstein, R., et al (1994) Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessment. Psychiatry Research, 54, 51-58.
11. Beneke, M. & Rasmus, W. (1992) Clinical Global Impressions (ECDEU): some critical comments. Pharmacopsychiatry, 25, 171-176.
12. Birsoz, S., Isik, E., Yargic, I., et al (2006) Remission in schizophrenia: a utopia or a goal? Klinik Psikofarmakoloji Buelteni, 16, 128-132.
13. Bozikas, V., Kosmidis, M., Gamvrula, K., et al (2004) Clock Drawing Test in patients with schizophrenia. Psychiatry Research, 121, 229-238.
14. Chadwick, P. & Birchwood, M. (1995) The omnipotence of voices. II: The Beliefs About Voices Questionnaire (BAVQ). British Journal of Psychiatry, 166, 773-776.
15. Collins, A., Remington, G., Coulter, K., et al (1996) Depression in schizophrenia: a comparison of three measures, Schizophrenia Research, 20, 205-209.
16. Cramer, J., Rosenheck, R., Xu, W., et al (2001) Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophrenia Bulletin, 27, 227-234.
17. Crow, T. (1980) Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry, 137, 383-386.
18. d'Amato, T., Rochet, T., Dalery, J., et al (1992) Relationship between symptoms rated with the Positive and Negative Syndrome Scale and Brain Measures in schizophrenia. Psychiatry Research, 44, 55-62.
19. Delmonte, P., Gabrielli, F., Gibertie, F., et al (1970) Diagnostic classification concepts among Italian psychiatrists. Archivio di Psicologia Neurologia e Psychiatria, 6, 531-553.
20. Dunayevich, E., Sethuraman, G., Enerson, M., et al (2006) Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophrenia Research, 86, 300-308.
21. Eckert, S., Diamond, P., Miller, A., et al (1996) A comparison of instrument sensitivity to negative symptom change. Psychiatry Research, 63, 67-75.
22. Emsley, R., Oosthuizen, P., Joubert, A., et al (1999) Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. Journal of Clinical Psychiatry, 60, 747-751.
23. Emslie, G., Rush, A., Weinberg, W., et al (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54, 1031-1037
24. Engelsmann, F. & Formankova, M. (1967) Abbreviated Psychiatric Evaluation Scale (Overall-Gorham). Ceskoslovenska Psychiatrie, 63, 297-306.
25. Engelsmann, F., Finar, O., Pichot, P., et al (1970) International comparison of diagnostic patterns. Transcultural Psychiatric Research Review, 7, 130-137.
26. Fresan, A., De la Fuente-Sandoval, C., Loyzaga, C., et al (2005) A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients. Schizophrenia Research, 72, 123-129.
27. Gharabawi, G., Rodriguez, S., Turkoz, I., et al (2005) Exploring the evidence for a relationship between symptomatic remission and functioning in patients with schizophrenia. Neuropsychopharmacology, 30 (suppl. 1), s1-s270.
28. Good, K., Rabinowitz, J., Whitehorn, D., et al (2004) The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophrenia Research, 68, 11-19.
29. Guy, W. (1976) Clinical Global Impression. In ECDEU Assessment Manual for Psychopharmacology (revised), pp. 217-221. National Institute of Mental Health.
30. Hamera, E., Schneider, J., Potocky, M., et al (1996) Validity of self-administered symptom scales in clients with schizophrenia and schizoaffective disorders. Schizophrenia Research, 19, 213-219.
31. Hamilton, S., Revicki, D., Genduso, L., et al (1998) Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology, 18, 41-49.
32. Haro, J., Kamath, S., Ochoa, S., et al (2003) The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica, 107 (suppl. 416), 16-23.
33. Hedlund, J. & Vieweg, B. (1980) The brief psychiatric rating scale (BPRS): a comprehensive review. Journal of Operational Psychiatry, 11, 48-65.
34. Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
35. Kay, S., Fiszbein, A., & Opler, L. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 262-276.
36. Kay, S., Opler, L., & Lindenmayer, J. (1988) Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenia. Psychiatry Research, 23, 99-110.
37. Kay, S., Opler, L., & Lindenmayer, J. (1989) The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry, 155 (suppl. 7), 59-67.
38. Kissling, W., Heres, S., Lloyd, K., et al (2005) Direct transition to long-acting risperidone - analysis of long-term efficacy. Journal of Psychopharmacology, 19, 15-21.
39. Krauss, H., Marwinski, K., Held, T., et al (1998) Reliability and validity of the premorbid adjustment scale (PAS) in a German sample of schizophrenic and schizoaffective patients. European Archives of Psychiatry in Clinical Neuroscience, 248, 277-281.
40. Lasser, R., Bossie, C., Gharabawi, G., et al (2005) Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophrenia Research, 77, 215-227.
41. Leucht, S. & Engel, R. (2006) The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology, 31, 406-412.
42. Leucht, S. & Lasser, R. (2006) The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry, 39, 161-170.
43. Leucht, S., Kane, J., Kissling, W., et al (2005a) Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry, 187, 366-371.
44. Leucht, S., Kane, J., Kissling, W., et al (2005b) What does the PANSS mean? Schizophrenia Research, 79, 231-238.
45. Leucht, S., Kane, J., Etschel, E., et al (2006) Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology, 1-8.
46. Lindenmayer, J., Kay, S. & Friedman, C. (1986) Negative and positive schizophrenic syndromes after the acute phase: A prospective follow-up. Comprehensive Psychiatry, 27, 276-286.
47. Lindenmayer, J., Bernstein-Hyman, R. & Grochowski, S. (1994) A new five factor model of schizophrenia. Psychiatric Quarterly, 65, 299-322.
48. Lindenmayer, J., Brown, E., Baker, R., et al (2004) An excitement subscale of the Positive and Negative Syndrome Scale. Schizophrenia Research, 68, 331-337.
49. Liu, S., Hwu, H. & Chen, W. (1997) Clinical sympton dimensions and deficits on the Continuous Performance Test in schizophrenia. Schizophrenia Research, 25, 211-219.
50. Marshall, M., Lockwood, A., Bradley, C., et al (2000) Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry, 176, 249-252.
51. Mass, R., Schoemig, T., Hitschfeld, K., et al (2000) Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale. Schizophrenia Bulletin, 26, 167-177.
52. McGorry, P., Goodwin, R. & Stuart, G. (1988) The development, use, and reliability of the brief psychiatric rating scale (nursing modification) - an assessment procedure for the nursing team in clinical and research settings. Comprehensive Psychiatry, 29, 575-587.
53. Mortimer, A. & Spence, S. (2001) The Management of Negative Symptom of Schizophrenia. Science Press.
54. Murray, R. & Van Os, J. (1998) Predictors of outcome in schizophrenia. Journal of Clinical Psychopharmacology, 18, 2S-4S.
55. Nasrallah, H. (2006) Improving patient outcomes in schizophrenia: achieving remission. Journal of Psychopharmacology, 20, 57-61.
56. Norman, R., Malla, A., Cortese, L., et al (1996) A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophrenia Reseorch, 19, 73-85.
57. Overall, J. & Gorham, D. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799-812.
58. Overall, J. & Pfefferbaum, B. (1982) The Brief Psychiatric Rating Scale for Children. Psychopharmacology Bulletin, 18, 10-16.
59. Overall, J. E. & Rhoades, H. M. (1982) Refinement of phenomenological classification in clinical psychopharmacology research. Psychopharmacology, 77, 24-30.
60. Overall, J. & Beller, S. (1984) The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. Journal of Gerontology, 39, 187-193.
61. Overall, J. & Gorham, D. (1988) The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacology Bulletin, 24, 97-99.
62. Peralta, V. & Cuesta, M. (1994) Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psychiatry Research, 53, 31-40.
63. Perry, P., Sanger, T. & Beasley, C. (1997) Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. Journal of Clinical Psychopharmacology, 17, 472-477.
64. Pogue-Geile, M. & Harrow, M. (1984) Negative and positive symptoms in schizophrenia and depression: A follow up. Schizophrenia Bulletin, 10, 371-387.
65. Rabinowitz, J., Mehnert, A. & Eerdekens, M. (2006) To what extent do the PANSS and CGI-S overlap? Journal of Clinical Psychopharmacology, 26, 303-307.
66. Ritsner, M., Blumenkrantz, H., Dubinsky, T., et al (2006) The detection of neurocognitive decline in schizophrenia using the Mindstreams Computerized Cognitive Test Battery. Schizophrenia Research, 82, 39-49.
67. Rocca, P., Bellino, S., Calvarese, P., et al (2005) Depressive and negative symptoms in schizophrenia: different effects on clinical features. Comprehensive Psychiatry, 46, 304-310.
68. Schuldberg, D., Quinlan, D. & Glazer, W. (1999) Positive and negative symptoms and adjustment in severely mentally ill outpatients. Psychiatry Research, 85, 177-188.
69. Sethuraman, G., Taylor, C., Enerson, M., et al (2005) A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophrenia Research, 79, 337-340.
70. Singh, M. & Kay, S. (1975) A comparative study of haloperidol and chtorpromazine in terms of clinical effects and therapeutic reversal; with benztropine in schizophrenia: theorectical implications for potency differences among neuroleptics. Psychopharmacologia, 43, 103-113.
71. Spearing, M., Post, R., Leverich, G., et al (1997) Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness: the CGI-BP. Psychiatry Research, 73, 159-171.
72. Steinert, T., Wolfle, M. & Gebhardt, R. (2000) Measurement of violence during in-patient treatment and association with psychopathology. Acta Psychiatrica Scandinavica, 102, 107-112.
73. Tiihonen, J., Wahlbeck, K., Lonnqvist, J., et al (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal, 331, 224.
74. Van den Oord, E., Rujescu, D., Robies, J., et al (2006) Factor structure and external validity of the PANSS revisited. Schizophrenia Research, 82, 213-223.
75. van der Gaag, M., Cuijpers, A., Hoffman, T., et al (2006a) The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. Schizophrenia Research, 85, 273-279.
76. van der Gaag, M., Hoffman, T., Remijsen, M., et al (2006b) The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophrenia Research, 85, 273-279.
77. Van Os, J., Fahy, T., Jones, P., et al (1996) Psychopathological syndromes in the functional psychoses: associations with course and outcome. Psychological Medicine, 26, 161-176.
78. Van Os, J., Burns, T., Cavallero, R., et al (2006) Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica, 113, 91-95.
79. Ventura, J., Neuchterlein, K. S. K., Gutkind, D., et al (2000) Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Research, 97, 129-135.
80. Welham, J., Stedman, T. & Clair, A. (1999) Choosing negative symptom instruments: issues of representation and redundancy. Psychiatry Research, 87, 47-56.
81. White, L. (2005) Interpreting the PANSS: measures, factors and models. Schizophrenia Research, 79, 349-351.
82. Wolthaus, J., Dingemans, P., Schene, A., et al (2000) Component structure of the Positive and Negative Syndrome Scale (PANSS) in patients with recent-onset schizophrenia and spectrum disorders. Psychopharmacology, 150, 399-403.